Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
Adial Pharmaceuticals, Inc (ADIL)
US:NASDAQ Investor Relations:
adialpharma.com
Company Research
Source: GlobeNewswire
GLEN ALLEN, Va., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent. The patent, once issued, will expand Adial's intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder (AUD). The new patent covers additional genotype combinations identified through the Company’s proprietary genetic diagnostic tool, further enhancing the precision medicine approach of AD04. “This Notice of Allowance represents an important milestone for Adial as we continue to broaden our patent estate,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “Securing protection for these additional genotype combinations provides us wit
Show less
Read more
Impact Snapshot
Event Time:
ADIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADIL alerts
High impacting Adial Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
ADIL
News
- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewswire
- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
ADIL
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 4
- 11/18/24 - Form 3
- ADIL's page on the SEC website